Grey Matters Health(AGNPF)
$0.18-0.06 (-25.42%)
AGNPF
Grey Matters Health stock drug pipeline
$0.18
At close:-0.06 (-25.42%)
Grey Matters Health (AGNPF) Drug Pipeline
75 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| N,N-Dimethyltryptamine | Stroke | Phase I | Active Not Recruiting | Single and Repeat Doses of DMT in Healthy Subjects | Sep 14, 2022 | ― |
| Np-120 (Ifenprodil) | Covid | phase2AndPhase3 | Completed | Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease | May 08, 2020 | ― |
| Ifenprodil | Idiopathic Pulmonary Fibrosis | Phase II | Completed | Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough | Mar 20, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| N,N-Dimethyltryptamine | Phase I | Stroke | Active Not Recruiting | Single and Repeat Doses of DMT in Healthy Subjects | Sep 14, 2022 | ― |
| Np-120 (Ifenprodil) | phase2AndPhase3 | Covid | Completed | Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease | May 08, 2020 | ― |
| Ifenprodil | Phase II | Idiopathic Pulmonary Fibrosis | Completed | Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough | Mar 20, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Grey Matters Health Inc (AGNPF) have in its pipeline
Grey Matters Health AGNPF is currently developing the following drugs: N,N-Dimethyltryptamine, Np-120 (Ifenprodil), Ifenprodil. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

